Meta-analysis: Acalabrutinib showed better PFS and OS than other frontline CLL therapiesOctober 7, 2020CLL
Two new protein biomarkers may serve as prognostic indicators for outcomes in CLLSeptember 23, 2020CLL
Survey quantifies COVID-19’s impact on oncologySeptember 20, 2020COVID-19 UpdatesDLBCLAggressive LymphomasALLAMLAnemiaCLL
BALL score predicts benefit from ibrutinib therapy in relapsed/refractory CLL patientsAugust 11, 2020CLL
